Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10465341 | 0.85 | PPARA (0.57) | KCNH2 | |
| SCHEMBL12700407 | 0.80 | NPC1 (0.56) | ABL1KCNH2NPC1RAB9A | |
| SCHEMBL10466908 | 0.73 | PPARA (0.43) | — | |
| SCHEMBL11433073 | 0.72 | CCR6 (0.43) | ABL1KCNH2TRPV1 | |
| SCHEMBL24143786 | 0.72 | TRPV1 (0.54) | NPC1RAB9ATRPV1 | |
| SCHEMBL25454601 | 0.72 | NOS3 (0.46) | ABL1KCNH2SCN10A | |
| SCHEMBL9886318 | 0.71 | CCR6 (0.42) | ABL1KCNH2TRPV1 | |
| SCHEMBL17157370 | 0.71 | ABL1 (0.49) | ABL1NPC1RAB9A | |
| SCHEMBL17157486 | 0.71 | ABL1 (0.49) | ABL1SCN10ANPC1RAB9A | |
| SCHEMBL9772021 | 0.70 | CYP1A2 (0.63) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646418-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS PARASITIC AGENTS | BAYER IP GMBH (DE) | 2017-10-04 | — | — | EP | disclosed |
| EP-2646418-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS PARASITIC AGENTS | BAYER IP GMBH (DE) | 2017-10-04 | — | — | EP | disclosed |
| US-9241487-B2 | Pyrimidine derivatives and use thereof as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-9241487-B2 | Pyrimidine derivatives and use thereof as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-9241487-B2 | Pyrimidine derivatives and use thereof as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-20140031373-A1 | PYRIMIDINE DERIVATIVES AND USE THEREOF AS PESTICIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20140031373-A1 | PYRIMIDINE DERIVATIVES AND USE THEREOF AS PESTICIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20140031373-A1 | PYRIMIDINE DERIVATIVES AND USE THEREOF AS PESTICIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| EP-2646418-A1 | PYRIMIDINE DERIVATIVES AND USE THEREOF AS PESTICIDES | Bayer Intellectual Property GmbH (DE) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012072547-A1 | PYRIMIDINE DERIVATIVES AND USE THEREOF AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012072547-A1 | PYRIMIDINE DERIVATIVES AND USE THEREOF AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031373-A1 | PYRIMIDINE DERIVATIVES AND USE THEREOF AS PESTICIDES | TYMP, TYMS, UMPS | ABL1 3618/4885KCNH2 3132/4885SCN10A 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.